Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00798226
Other study ID # H-B-2008-093
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date November 26, 2008
Est. completion date July 2027

Study information

Verified date February 2024
Source Copenhagen Studies on Asthma in Childhood
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to prevent asthma and allergies in childhood by supplementation with fish oil (n-3 fatty acids) to the mother during pregnancy. Paticipants are mother and children participating in the ABC-(Asthma Begins in Childhood)cohort. Mothers are recruited during pregnancy and receive supplement with n-3 fatty acids or olive oil (placebo) from week 24 of gestation to 1 week after delivery. The child is followed with acute and planned visit at the research unit and diagnosis of disease is done in the research unit according to predefined algorithms.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 800
Est. completion date July 2027
Est. primary completion date July 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria (mother): - Pregnant women - Living in Sealand, Denmark - Fluent in Danish Language - Willing to let the newborn child participate in the study Exclusion Criteria (mother): - Participating in other clinical trial

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
n-3 fatty acid
Oral intake of 4 capsules daily from week 24 of gestation to 1 week after delivery
olive oil
Oral intake of 4 capsules (1 g) daily from 24 weeks of gestation to 1 week after delivery

Locations

Country Name City State
Denmark Copenhagen University Hospital of Copenhagen Gentofte
Denmark Næstved Hospital, Pediatric Department Næstved

Sponsors (1)

Lead Sponsor Collaborator
Copenhagen Studies on Asthma in Childhood

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Asthma Asthma diagnosed from age 3 to 10 years based on the same predefined algorithm of recurrent troublesome lung symptoms, response to treatment after withdrawal of treatment, which was used for persistent wheeze at age 0-3 in phase 1 of the study. Primary outcome in phase 2 is current asthma at specific visits till age 10 years, which is diagnosed in children fulfilling the persistent wheeze algorithm at any point during the first 10 years of life and still needing inhaled corticosteroids at specific visits (3, 4, 5, 6, 8 and 10 years of age) to control the symptoms. 3-10 years of age
Other Infections Prescribed medicine for infections. Types and length of infections 3-10 years of age
Other Weight Clinical follow up on the development of weight in kg (calibrated digital weight scales) at every visit till age 10 years assessed longitudinally in the research clinic. 3-10 years of age
Other Behavioral and psychopathological dimensions. Behavioral and psychopathological dimensions will be assessed at 10 years of age.
The childrens' potential psychiatric diagnoses will be ascertained through the semi-structured clinical interview Schedule for Affective Disorders and Schizophrenia for School-Age Children - Present and Lifetime Version (K-SADS-PL) first with a parent and next with the child.
10 years of age
Other MRI scanning of the brain MRI scanning of the brain. The scanning procedure will take up to 1 hour. 10 years of age
Other Eczema Age at onset of eczema diagnosed prospectively by research doctors according to predefined algorithm based upon Hanifin and Rajka criteria. 3-10 years of age
Other Allergic sensitization/atopy Allergic sensitization at 6 and 10 years of age assessed by skin prick test (ALK-Abelló, Denmark). 6-10 years of age
Other Airway mucosal immune status: Immune status measured in airway mucosal lining fluid at 3, 6 and 10 years of age (combined assessments by principal component analyses for each age point). 3-10 years of age
Other Allergic rhinitis Allergic rhinitis will be diagnosed by combining allergic sensitization with symptom recording of troublesome congestion or sneezing or runny nose upon relevant exposure to allergens at age 3, 4, 5, 6, 8 and 10 years. 3-10 years of age
Other Lung function measurements Spirometry measuring airflow in liter. Compared with age and sex validated standards [Time Frame: 5-10 years of age]
Other Cognitive function A 2,5 hours cognitive evaluation at 10 years of age. Cognitive functions from a broad spectrum of cognitive domains will be assessed with subtests both using paper pencil tests and Cambridge Neuropsychological Test Automated Battery . 10 years of age
Other Asthma exacerbations: Age at onset and number of severe asthma exacerbation diagnosed by predefined criteria of acute severe asthma requiring oral/ high dose inhaled steroids or acute hospital contact [Time Frame: 3-10 years of age]
Other Body composition: Body composition measured as fat mass, lean mass, bone mineral content (BMC) and bone mineral density assessed (BMD) through DXA scans at 6 years of age.
Body impedance measurements at 10 years of age.
[Time Frame: 3-10 years of age]
Other Airway resistance sRaw measured by plethysmography at age 3, 4, 5, 6, 8 and 10 years. [Time Frame: 3-10 years of age]
Other Airway resistance Multiple breath wash-out using SF6 and N2 as inert gasses to determined LCI, Scond and Sacin at ages 3, 4 and 5 years. [Time Frame: 3-5 years of age]
Other Bronchial reactivity: Provocative dose of methacholine leading to a 20% drop in FEV1 from baseline (PD20 value) at age 6 years. 6 years of age.
Other Airway inflammation: Measurement of fractional exhaled nitric oxide (FeNO) at age 6, 8 and 10 years [Time Frame: 6-10 years of age]
Other Height Clinical follow up on the development of height in cm (Harpenden stadiometer) at every visit till age 10 years assessed longitudinally in the research clinic. [Time Frame: 3-10 years of age]
Other Waistcircumference Clinical follow up on the development of waistcircumference in cm(using tape; 3 times each) at every visit till age 10 years assessed longitudinally in the research clinic. [Time Frame: 3-10 years of age]
Other Headcircumference Clinical follow up on the development of headcircumference in cm(using tape; 3 times each) at every visit till age 10 years assessed longitudinally in the research clinic. [Time Frame: 3-10 years of age]
Other Thoraxcircumference Clinical follow up on the development of thoraxcircumference in cm(using tape; 3 times each) at every visit till age 10 years assessed longitudinally in the research clinic. [Time Frame: 3-10 years of age]
Other Strength and Difficulties Questionnaire (SDQ)- Questionnaires The Strengths and Difficulties Questionnaire (SDQ) is a brief behavioural screening questionnaire about 3-16 year olds. Questionnaires will be administered to the parents to obtain their evaluation of their child's potential psychopathology and behavior problems. Scores will be calculated form the questionnaires in order validated methods 6, 8 and 10 years of age.
Other ADHD- RS- Questionnaires The ADHD Rating Scale obtains parent ratings regarding the frequency of each ADHD symptom based on DSM criteria.
Questionnaires will be administered to the parents to obtain their evaluation of their child's potential psychopathology and behavior problems. Scores will be calculated form the questionnaires. Scores will be calculated form the questionnaires in order validated methods.
8 and 10 years of age.
Other Social Responsive Scale, Second version (SRS-2) The SRS-2 identifies social impairment associated with autism spectrum disorders (ASDs) and quantifies its severity Questionnaires will be administered to the parents to obtain their evaluation of their child's potential psychopathology. Scores will be calculated form the questionnaires. Scores will be calculated form the questionnaires in order validated methods. 10 years of age
Other The Behavior Rating Inventory of Executive Function 2nd edition (BRIEF-2) The BRIEF-2 is a set of questionnaires for parents and teachers , designed to evaluate executive function from multiple perspectives.
Questionnaires will be administered to the parents to obtain their evaluation of their child's potential psychopathology. Scores will be calculated form the questionnaires. Scores will be calculated form the questionnaires in order validated methods.
10 years of age
Other The Child Behavior Checklist school-age version (CBCL) The Child Behavior Checklist (CBCL) is a widely used questionnaire to assess behavioral and emotional problems.
Questionnaires will be administered to the parents to obtain their evaluation of their child's potential psychopathology and behavior problems. Scores will be calculated form the questionnaires. Scores will be calculated form the questionnaires in order validated methods.
10 years of age
Other Allergic sensitization Allergic sensitization assessed specific IgE in blood (ImmunoCAP, PHarmacia Diagnostics AB, Sweden). 6 and 10 years of age
Primary Persistent wheeze 0 to 3 years of age Age at onset of persistent wheeze diagnosed according to predefined algorithm of recurrent troublesome lung symptoms, response to treatment and relapse after withdrawal of treatment 3 years
Secondary Asthma exacerbations Age at onset of severe asthma exacerbation diagnosed by predefined criteria of acute severe asthma requiring oral/high dose inhaled steroids or acute hospital contact 0-3 years
Secondary Infections Main analysis:
• Number of lower respiratory tract infections registered in daily diaries
Secondary analyses:
Acute otitis media
Number of upper respiratory tract infections
Number of other infections
Total number of infections
0-3 years of age
Secondary Growth Body composition (fat mass and bone mineral density) assessed by DEXA scan at 3 years of age
Development of BMI from birth to 3 years assesses longitudinally in the research clinic
0 to 3 years of age
Secondary Neurological development Main analysis:
• Cognitive development assessed at 2½ years using the cognitive part of Bayley Scales of Infant and Toddler Development, third edition
Secondary analyses:
Milestone development monitored prospectively by the parents using a registration form based on The Denver Development Index and WHO milestones registration (combined assessment by principal component analysis)
Language development assessed at 1 and 2 years of age with the Danish version of The MacArthur Bates Communicative Developmental Inventory (CDI)
The child´s general development (language, fine and gross motor, social and problem solving) at 3 years of age assessed with Ages and stages Questioner, third edition (ASQ-3)
0-3 years
Secondary Eczema Age at onset of eczema diagnosed prospectively by research doctors according to predefined algorithm based upon Hanifin and Rajka criteria 0-3 years
Secondary Allergic sensitization Allergic sensitization at 6 and/or 18 months of age assessed by skin prick test and specific IgE in blood 6 and 18 months of age
Secondary Systemic immune status Main analysis
Immune status at 18 months measured in stimulated whole blood as cytokine release (combined assessments by prinicipal component analyses) Secondary analyses
Composition of immune cell subsets in whole blood at birth and at 18 months of age
18 months
Secondary Airway mucosal immune status Immune status measured in airway mucosal lining fluid at 4 weeks and 2 years of age (combined assessments by prinicipal component analyses for each age point) 4 weeks and 2 years of age
See also
  Status Clinical Trial Phase
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device